Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

Ting‐Chao Chou · Cancer Research · 2010 · 5.7K citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al. · Science Translational Medicine · 2011 · 3.6K citations · Full text

Medicine, Genetics, Oncology +17

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

Sreenath V. Sharma, Diana Lee, Bihua Li et al. · Cell · 2010 · 2.8K citations · Full text

Life Sciences, Cancer Biology, Oncology +14

A quantitative analysis of kinase inhibitor selectivity

Mazen W. Karaman, Sanna Herrgård, Daniel K. Treiber et al. · Nature Biotechnology · 2008 · 2.4K citations

Pharmacy, Medicinal Chemistry, Pharmacology +13